SCHEMBL184078

SCHEMBL184078

O=S(=O)(Nc1nccs1)c1ccc(Br)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.72
LMNA P02545 3/20 0.72
SMN1; SMN2 Q16637 2/20 0.72
KDM4E B2RXH2 1/20 0.72
CYP2C9 P11712 1/20 0.72
EDNRA P25101 1/20 0.72
SLC6A4 P31645 1/20 0.72
ADRA1A P35348 1/20 0.72
PRMT6 Q96LA8 1/20 0.72
TDP1 Q9NUW8 1/20 0.72
CYP1A2 P05177 1/20 0.65
PKM P14618 6/20 0.63
KMT2A Q03164 4/20 0.62
MEN1 O00255 2/20 0.62
ALOX12 P18054 1/20 0.61
POLB P06746 2/20 0.61
ATM Q13315 1/20 0.60
DNMT1 P26358 1/20 0.57
BLM P54132 1/20 0.57
HKDC1 Q2TB90 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12838834 0.94 ALDH1A1 (0.70) ALDH1A1LMNASMN1; SMN2KDM4ECYP2C9
SCHEMBL3066836 0.85 LMNA (0.79) ALDH1A1LMNASMN1; SMN2KDM4ECYP2C9
SCHEMBL13212137 0.85 MEN1 (0.79) ALDH1A1LMNAKDM4ETDP1PKM
Sulfathiazole SCHEMBL30130508 0.84 ALDH1A1 (1.00) ALDH1A1LMNASMN1; SMN2KDM4ECYP2C9
Sulfathiazole SCHEMBL94165 0.84 ALDH1A1 (1.00) ALDH1A1LMNASMN1; SMN2KDM4ECYP2C9
SCHEMBL1650814 0.84 ALDH1A1 (0.72) ALDH1A1LMNASMN1; SMN2KDM4ECYP2C9
SCHEMBL13180843 0.84 ALDH1A1 (0.72) ALDH1A1LMNASMN1; SMN2KDM4ECYP2C9
SCHEMBL8388562 0.84 PPIA (0.76) ALDH1A1LMNASMN1; SMN2KDM4ECYP2C9
SCHEMBL183995 0.84 ALDH1A1 (0.72) ALDH1A1LMNASMN1; SMN2KDM4ECYP2C9
SCHEMBL326633 0.83 ALDH1A1 (0.71) ALDH1A1LMNASMN1; SMN2KDM4ECYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3054936-B1 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS EASTERN VIRGINIA MEDICAL SCHOOL (US) 2023-10-18 EP disclosed
US-11274077-B2 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase EASTERN VIRGINIA MEDICAL SCHOOL (US) 2022-03-15 US disclosed
US-20200392077-A1 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO)BENZENESULFONAMIDE DERIVATIVES AS POTENT AND SELECTIVE INHIBITORS OF 12-LIPOXYGENASE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-12-17 US disclosed
US-10752581-B2 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase EASTERN VIRGINIA MEDICAL SCHOOL (US) 2020-08-25 US disclosed
US-10752581-B2 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase EASTERN VIRGINIA MEDICAL SCHOOL (US) 2020-08-25 US disclosed
US-20190276395-A1 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO)BENZENESULFONAMIDE DERIVATIVES AS POTENT AND SELECTIVE INHIBITORS OF 12-LIPOXYGENASE NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-09-12 US disclosed
US-10266488-B2 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase EASTERN VIRGINIA MEDICAL SCHOOL (US) 2019-04-23 US disclosed
US-20170001955-A1 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide Derivatives as Potent and Selective Inhibitors of 12-Lipoxygenase THOMAS JEFFERSON UNIVERSITY 2017-01-05 US disclosed
EP-3054936-A1 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS Eastern Virginia Medical School (US) 2016-08-17 EP disclosed
WO-2015054662-A1 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO) BENZENESULFONAMIDE DERIVATIVES AS 12-LIPOXYGENASE INHIBITORS EASTERN VIRGINIA MEDICAL SCHOOL (US) 2015-04-16 WO disclosed
US-20090023740-A1 SODIUM CHANNEL INHIBITORS ICAGEN (US) 2009-01-22 US disclosed
EP-1963281-A2 HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS Vertex Pharmaceuticals, Inc. (US) 2008-09-03 EP disclosed
EP-1922068-A2 INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS Icagen, Inc. (US) 2008-05-21 EP disclosed
US-20080027067-A1 Heterocyclic derivatives as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2008-01-31 US disclosed
US-20080027067-A1 Heterocyclic derivatives as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2008-01-31 US disclosed
US-20080027067-A1 Heterocyclic derivatives as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2008-01-31 US disclosed
WO-2007075895-A2 HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-07-05 WO disclosed
WO-2007075895-A2 HETEROCYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-07-05 WO disclosed
US-20070078145-A1 INHIBITORS OF ION CHANNELS ICAGEN (US) 2007-04-05 US disclosed
WO-2007021941-A2 INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS ICAGEN, INC. (US) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10266488-B2 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase ALOX12, ALOX15, ALOX15B ALDH1A1 3051/4885LMNA 1518/4885SMN1; SMN2 3002/4885
US-20200392077-A1 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO)BENZENESULFONAMIDE DERIVATIVES AS POTENT AND SELECTIVE INHIBITORS OF 12-LIPOXYGENASE ALOX12, ALOX15, ALOX15B ALDH1A1 3051/4885LMNA 1518/4885SMN1; SMN2 3002/4885
US-11274077-B2 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase ALOX12, ALOX15, ALOX15B ALDH1A1 3051/4885LMNA 1518/4885SMN1; SMN2 3002/4885
US-20080027067-A1 Heterocyclic derivatives as modulators of ion channels TRPV1, KCNJ2, KCNN3 ALDH1A1 1645/4885LMNA 2366/4885SMN1; SMN2 1123/4885
US-20090023740-A1 SODIUM CHANNEL INHIBITORS TRPV1, SCN1A, SCN2A ALDH1A1 3333/4885LMNA 2921/4885SMN1; SMN2 287/4885
US-20190276395-A1 4-((2-HYDROXY-3-METHOXYBENZYL)AMINO)BENZENESULFONAMIDE DERIVATIVES AS POTENT AND SELECTIVE INHIBITORS OF 12-LIPOXYGENASE ALOX12, ALOX15, ALOX15B ALDH1A1 3051/4885LMNA 1518/4885SMN1; SMN2 3002/4885
US-20070078145-A1 INHIBITORS OF ION CHANNELS TRPV1, TRPA1, CACNA1B ALDH1A1 3009/4885LMNA 3621/4885SMN1; SMN2 445/4885
US-10752581-B2 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide derivatives as potent and selective inhibitors of 12-lipoxygenase ALOX12, ALOX15, ALOX15B ALDH1A1 3051/4885LMNA 1518/4885SMN1; SMN2 3002/4885
US-20170001955-A1 4-((2-hydroxy-3-methoxybenzyl)amino)benzenesulfonamide Derivatives as Potent and Selective Inhibitors of 12-Lipoxygenase ALOX12, ALOX15, ALOX15B ALDH1A1 3051/4885LMNA 1518/4885SMN1; SMN2 3002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.